Rani Therapeutics Holdings (NASDAQ: RANI) has announced the appointment of Michelle Gilson to its board of directors (BOD). Ms. Gilson will serve as chair of the audit committee.
Most recently, Ms. Gilson served as chief financial officer of Arcellx—acquired by Gilead this year. Prior to joining Arcellx, Ms. Gilson was a biotechnology equity research analyst at various leading investment banks, including Canaccord Genuity, Jefferies, Nomura, Oppenheimer & Co., and Goldman Sachs.
In a statement, Talat Imran, CEO of Rani, commented, “The combination of deep capital markets expertise and hands-on financial leadership at a high-growth biotechnology company makes Michelle an exceptional addition to our board. Her experience guiding Arcellx through its partnership and acquisition by Gilead gives her a firsthand understanding of how disciplined financial strategy and strong corporate governance can translate into significant value creation. As we continue to advance our pipeline and pursue strategic opportunities, Michelle’s insight will be invaluable to Rani and our shareholders.”
